These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3093033)

  • 1. Treatment of psoriasis vulgaris by oral administration of 1 alpha-hydroxyvitamin D3--open-design study.
    Morimoto S; Yoshikawa K; Kozuka T; Kitano Y; Imanaka S; Fukuo K; Koh E; Onishi T; Kumahara Y
    Calcif Tissue Int; 1986 Sep; 39(3):209-12. PubMed ID: 3093033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open study of vitamin D3 treatment in psoriasis vulgaris.
    Morimoto S; Yoshikawa K; Kozuka T; Kitano Y; Imanaka S; Fukuo K; Koh E; Kumahara Y
    Br J Dermatol; 1986 Oct; 115(4):421-9. PubMed ID: 3022784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 1 alpha-hydroxycholecalciferol on psoriasis vulgaris: a pilot study.
    Takamoto S; Onishi T; Morimoto S; Imanaka S; Yukawa S; Kozuka T; Kitano Y; Seino Y; Kumahara Y
    Calcif Tissue Int; 1986 Dec; 39(6):360-4. PubMed ID: 3100000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1 alpha-hydroxyvitamin D3 in intestinal calcium malabsorption. A pilot study.
    Hylander E; Jarnum S
    Scand J Gastroenterol; 1980; 15(4):443-8. PubMed ID: 7433906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A patient with psoriasis cured by 1 alpha-hydroxyvitamin D3.
    Morimoto S; Kumahara Y
    Med J Osaka Univ; 1985 Mar; 35(3-4):51-4. PubMed ID: 4069059
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone.
    Birkenhäger-Frenkel DH; Pols HA; Zeelenberg J; Eijgelsheim JJ; Schot R; Nigg AL; Weimar W; Mulder PG; Birkenhäger JC
    J Bone Miner Res; 1995 Feb; 10(2):197-204. PubMed ID: 7754799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
    Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of osteomalacia associated with primary biliary cirrhosis with parenteral vitamin D2 or oral 25-hydroxyvitamin D3.
    Compston JE; Horton LW; Thompson RP
    Gut; 1979 Feb; 20(2):133-6. PubMed ID: 311747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriasis and vitamin D3. A review of our experience.
    Morimoto S; Yoshikawa K
    Arch Dermatol; 1989 Feb; 125(2):231-4. PubMed ID: 2536537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of vitamin D3 derivatives in the treatment of psoriasis vulgaris: a preliminary report.
    el-Azhary RA; Peters MS; Pittelkow MR; Kao PC; Muller SA
    Mayo Clin Proc; 1993 Sep; 68(9):835-41. PubMed ID: 8396699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observation on the use of 1 alpha-hydroxyvitamin D3 in the prevention of bovine parturient paresis: the effect of a single injection on plasma 1 alpha-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3, calcium, and hydroxyproline.
    Bar A; Perlman R; Sachs M
    J Dairy Sci; 1985 Aug; 68(8):1952-8. PubMed ID: 3840185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A trial of oral 1 alpha-hydroxyvitamin D3 for ichthyosis.
    Okano M; Kitano Y; Yoshikawa K
    Dermatologica; 1988; 177(1):23. PubMed ID: 3053274
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of 1 alpha-hydroxyvitamin D3 in the prevention of bovine parturient paresis. IX. Early and late effects of a single injection.
    Sachs M; Perlman R; Bar A
    J Dairy Sci; 1987 Aug; 70(8):1671-5. PubMed ID: 3668037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A low dose regime of 1 alpha hydroxyvitamin D3 in the management of senile osteoporosis: a pilot study.
    Cohen HN; Farrah D; Fogelman I; Goll CC; Beastall GH; McIntosh WB; Fletcher M; Boyle IT
    Clin Endocrinol (Oxf); 1980 Jun; 12(6):537-42. PubMed ID: 7398099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral administration of 1 alpha hydroxyvitamin D3 inhibits tumor growth and metastasis of a murine osteosarcoma model.
    Hara K; Kusuzaki K; Takeshita H; Kuzuhara A; Tsuji Y; Ashihara T; Hirasawa Y
    Anticancer Res; 2001; 21(1A):321-4. PubMed ID: 11299756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic trial of hematological disorders with intermittent administration of high-dose 1-alpha-hydroxyvitamin D3.
    Imai Y; Tsutsumi M; Tsunenari T; Nishikawa M; Matsui T; Natazuka T; Fujita T
    Contrib Nephrol; 1991; 91():95-101. PubMed ID: 1800016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoparathyroidism--a long-term follow-up experience with 1 alpha-vitamin D3 therapy.
    Halabe A; Arie R; Mimran D; Samuel R; Liberman UA
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):303-7. PubMed ID: 8187292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of bone disease after jejunoileal bypass for obesity with oral 1 alpha-hydroxyvitamin D3.
    Compston JE; Horton LW; Laker MF; Merrett AL; Woodhead JS; Gazet JC; Pilkington TR
    Gut; 1980 Aug; 21(8):669-74. PubMed ID: 7429331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteomalacia and celiac disease: response to 25-hydroxyvitamin D.
    Hepner GW; Jowsey J; Arnaud C; Gordon S; Black J; Roginsky M; Moo HF; Young JF
    Am J Med; 1978 Dec; 65(6):1015-20. PubMed ID: 742623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vitamin D 3 analogs, e new therapy for psoriasis].
    van de Kerkhof PC; de Jong EM; Arnold WP; de Mare S; Hol CW
    Ned Tijdschr Geneeskd; 1993 Jan; 137(5):232-6. PubMed ID: 8381921
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.